BibliographyBossa, F., Latiano, A., Rossi, L., Magnani, M., Palmieri, O., Dallapiccola, B., Serafini, S., Damonte, G., De, S.E., Andriulli, A., Annese, V., 2008. Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study. Am. J. Gastroenterol. [PubMed] Flower, R., Peiretti, E., Magnani, M., Rossi, L., Serafini, S., Gryczynski, Z., Gryczynski, I., 2008. Observation of Erythrocyte Dynamics in the Retinal Capillaries and Choriocapillaris Using ICG-loaded Erythrocyte Ghost Cells. Invest Ophthalmol. Vis. Sci. [PubMed] Pierige, F., Serafini, S., Rossi, L., Magnani, M., 2008. Cell-based drug delivery. Adv. Drug Deliv. Rev. 60, 286-295. [PubMed] Castro, M., Rossi, L., Papadatou, B., Bracci, F., Knafelz, D., Ambrosini, M.I., Calce, A., Serafini, S., Isacchi, G., D'Orio, F., Mambrini, G., Magnani, M., 2007. Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn disease. J. Pediatr. Gastroenterol. Nutr. 44, 423-426. [PubMed] Annese, V., Latiano, A., Rossi, L., Bossa, F., Damonte, G., Dallapiccola, B., Serafini, S., Pierige, F., Andriulli, A., Magnani, M., 2006. The polymorphism of multi-drug resistance 1 gene (MDR1) does not influence the pharmacokinetics of dexamethasone loaded into autologous erythrocytes of patients with inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 10, 27-31. [PubMed] Castro, M., Knafelz, D., Rossi, L., Ambrosini, M.I., Papadatou, B., Mambrini, G., Magnani, M., 2006. Periodic treatment with autologous erythrocytes loaded with dexamethasone 21-phosphate for fistulizing pediatric Crohn's disease: case report. J. Pediatr. Gastroenterol. Nutr. 42, 313-315. [PubMed] Rossi, L., Serafini, S., Pierige, F., Castro, M., Ambrosini, M.I., Knafelz, D., Damonte, G., Annese, V., Latiano, A., Bossa, F., Magnani, M., 2006. Erythrocytes as a controlled drug delivery system: clinical evidences. J. Control Release 116, e43-e45. [PubMed] Annese, V., Latiano, A., Rossi, L., Lombardi, G., Dallapiccola, B., Serafini, S., Damonte, G., Andriulli, A., Magnani, M., 2005. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients-a pilot uncontrolled study. Am. J. Gastroenterol. 100, 1370-1375. [PubMed] Rossi, L., Serafini, S., Pierige, F., Antonelli, A., Cerasi, A., Fraternale, A., Chiarantini, L., Magnani, M., 2005. Erythrocyte-based drug delivery. Expert. Opin. Drug Deliv. 2, 311-322. [PubMed] Rossi, L., Castro, M., D'Orio, F., Damonte, G., Serafini, S., Bigi, L., Panzani, I., Novelli, G., Dallapiccola, B., Panunzi, S., Di, C.P., Bella, S., Magnani, M., 2004. Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. Blood Cells Mol. Dis. 33, 57-63. [PubMed] The European Medicinal Agency (EMEA) has granted the state of orphan drug designation to this treatment for cystic fibrosis patients (Orphan Drug Designation EMEA/OD/039/04-EU/3/04/230) Rossi, L., Serafini, S., Cenerini, L., Picardi, F., Bigi, L., Panzani, I., Magnani, M., 2001. Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease. Biotechnol. Appl. Biochem. 33, 85-89. [PubMed] Magnani, M., Rossi, L., D'Ascenzo, M., Panzani, I., Bigi, L., Zanella, A., 1998. Erythrocyte engineering for drug delivery and targeting. Biotechnol. Appl. Biochem. 28 ( Pt 1), 1-6. [PubMed] Patents: “Method of encapsulating biologically active agents within erythrocytes, and apparatus thereof” EU (Italy, France, Germany, UK and the Netherlands) N. 00882448, granted on 12 January 2005; USA N. 6,139,836, granted on 31 October 2000 ; Japan N. 123228/98, filed on 6 May 1998 |
EryDel SPA |